CTNM trades 62.6% below Wall Street's consensus target of $21.33.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CTNM achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 4 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Contineum Therapeutics, Inc. (CTNM) has a Wall Street consensus price target of $21.33, based on estimates from 4 covering analysts. With the stock currently trading at $13.12, this represents a potential upside of +62.6%. The company has a market capitalization of $491M.
Analyst price targets range from a low of $17.00 to a high of $28.00, representing a 52% spread in expectations. The median target of $19.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CTNM trades at a trailing P/E of -6.0x. Analysts expect EPS to grow -12.1% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 PRTAProthena Corporation plc | $438M | $8.36 | $30.00 | +258.9% | Buy | 76.0x | 28 |
 ARQTArcutis Biotherapeutics, Inc. | $3.1B | $25.16 | $38.00 | +51.0% | Buy | 50.6x | 12 |
 KYMRKymera Therapeutics, Inc. | $8.8B | $107.39 | $138.07 | +28.6% | Buy | — | 27 |
 TERNTerns Pharmaceuticals, Inc. | $4.8B | $52.95 | $51.40 | -2.9% | Buy | — | 16 |
 ACADACADIA Pharmaceuticals Inc. | $3.4B | $19.95 | $32.32 | +62.0% | Buy | 32.4x | 37 |
 INVAInnoviva, Inc. | $1.5B | $20.50 | $38.00 | +85.4% | Buy | 8.5x | 10 |
 PTGXProtagonist Therapeutics, Inc. | $9.0B | $140.06 | $176.29 | +25.9% | Buy | 30.0x | 26 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 RXRXRecursion Pharmaceuticals, Inc. | $2.2B | $4.12 | $5.30 | +28.6% | Hold | — | 10 |
Quick answers to the most common questions about buying CTNM stock.
The consensus Wall Street price target for CTNM is $21.33, representing 62.6% upside from the current price of $13.12. With 4 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
CTNM has a consensus rating of "Buy" based on 4 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $21.33 implies 62.6% upside from current levels.
CTNM's current price is $13.12 with a consensus target of $21.33 (62.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $28 for CTNM, while the most conservative target is $17. The consensus of $21.33 represents the median expectation. These targets typically reflect 12-month expectations.
CTNM is lightly followed, with 4 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CTNM stock forecast based on 4 Wall Street analysts shows a consensus price target of $21.33, with estimates ranging from $17 (bear case) to $28 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on CTNM, with a "Buy" consensus rating and $21.33 price target (62.6% upside). 3 of 4 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CTNM analyst price targets range from $17 to $28, a 52% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21.33 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.